Price movement over the last 24 hours
Amazon.com Inc vs Nuvalent Inc — how do they compare? Amazon.com Inc trades at $244.66 (market cap $2.64T), while Nuvalent Inc trades at $123.9 (market cap $9.80B). The key difference: Amazon.com Inc is far larger — about 269.4× Nuvalent Inc's market cap, and Nuvalent Inc is trading nearer its 52-week high, Amazon.com Inc nearer its low. Which is the better fit depends on your goals.
| AMZN | NUVL | |
|---|---|---|
Market Cap | $2.64T | $9.80B |
Volume | 3,931,282 | — |
Sector | Consumer Cyclical | Technology |
52-Week High | $274.95 | $123.90 |
52-Week Low | $198.79 | $72.16 |
Enterprise Value | $2.71T | $8.52B |
Signals from Pluang's Aura AI — not financial advice
Amazon (AMZN) trades at $245.34, down 0.69% on the day, with a bullish technical outlook supported by moving averages. The company reported strong Q1 2026 earnings, beating expectations with EPS of $2.78, and shows robust revenue growth, reaching $716.92B in 2025. Operating cash flow remains strong at $139.51B, though heavy investing activities result in modest net cash flow. Analyst sentiment is overwhelmingly positive, with 88.3% recommending Buy and a consensus price target of $320.75.
The outlook for Amazon is favorable, driven by AI advancements in AWS and expanding market penetration. Key risks include intense competition in retail and cloud sectors, high capital expenditures, and macroeconomic pressures. Investors should weigh the strong growth trajectory against these risks, with the stock offering significant upside based on analyst targets.
Nuvalent (NUVL) trades at $123.9, up 0.06% on the day, following GSK's $10.6 billion all-cash acquisition offer at $124 per share announced on June 9, 2026 (Reuters). The stock is near the acquisition price, with bullish technical signals from moving averages but overbought RSI readings. Financially, the company reports negative earnings and cash flow from operations, with a P/B ratio of 8.35. Recent news highlights multiple law firms investigating the fairness of the deal.
The acquisition by GSK provides a clear exit near current levels, limiting upside but reducing volatility. Key risks include deal completion uncertainty and shareholder litigation. Analyst sentiment is mixed with 42% buy ratings. Investors should weigh the guaranteed offer against fundamental weaknesses and legal scrutiny.
Trailing returns across standard periods
Latest headlines on both assets
Amazon.com, Inc. is an online retailer that offers a wide range of products. The Company products include books, music, computers, electronics and numerous other products. Amazon offers personalized shopping services, Web-based credit card payment, and direct shipping to customers. Amazon also operates a cloud platform offering services globally.
Read more on AMZN →Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →